The study of viral infectivity and detection of viral capsid antigens of the major cervical cancer-associated human papillomavirus (HPV) type, HPV-16, requires knowledge of which epitopes are exposed in clinical specimens of infected tissue or on intact capsids. To define the antigenic epitopes ofHPV-16, antisera to 66 overlapping synthetic peptides corresponding to the HPV-16 capsid proteins L1 and L2 and to seven peptide analogues were tested in immunoperoxidase stainings of consecutive sections from formalin-fixed, paraffin-embedded HPV infected tissue. Antisera against eleven different peptides from L1 and against seven different peptides from L2 recognized the HPV capsid antigen. Most epitopes were only found on the capsid antigen of certain genital HPV types, but four antigenic epitopes in L1 were detectable also in cutaneous wart specimens. All antigenic epitopes in L2 were restricted to genital HPV types and four L2 epitopes were only detectable in HPV-16 or HPV-33 positive specimens. The surface exposure of the antigenie epitopes was investigated by comparing the reactivity of the antipeptide antisera with intact or disrupted virions or capsids of HPV-11, HPV-16 and bovine papillomavirus (BPV). Twenty antipeptide sera from L1 and seven antipeptide sera from L2 were reactive with intact HPV-16 capsids at titres up to 1 : 146000. Sixteen of these antisera were also reactive with disrupted HPV-16 capsids. Cross-reactivity with disrupted HPV-11 and BPV was detected for eleven and six antisera, respectively, whereas intact HPV-11 or BPV virions showed only weak cross-reactivity. In conclusion, the HPV-16 L1 and L2 capsid proteins contained multiple antigenic epitopes, most of which were shared with one or several additional HPV types.
Introduction
The human papillomaviruses (HPVs) cause a variety of proliferative epithelial lesions, from common warts to premalignant intraepithelial neoplasias of the anogenital region (zur Hausen, 1991) . Thus far, 68 different types of human papillomavirus (HPV) have been isolated (de Villiers, 1992) . HPV types 16 and 18 are the predominant types found in human anogenital cancers and high-grade intraepithelial neoplasias (Lorincz et al., 1992) , whereas HPV types 6 and 11 cause genital warts (condylomas) and low grade dysplasias, but are extremely rare in cancers (Pfister, 1987; zur Hausen, 1991) . HPV types 31, warts usually produce large amounts of virions, longstanding cutaneous warts less frequently produce viral capsids (Barrera-Oro et al., 1962). However, longitudinal studies of viral capsid antigen expression or shedding of virus particles are lacking for the malignancy-associated HPVs. Monospecific antibodies against defined HPV capsid antigen epitopes might be useful for such studies.
Neutralizing monoclonal antibodies against cottontail rabbit papillomavirus (CRPV) (Christensen et The fact that immunization with intact virions predominantly generates antibodies against conformationally dependent epitopes indicates that these epitopes are very immunogenic (Kirnbauer et al., 1992) . Since it appears improbable that no linear stretches of amino acids are exposed on the virion surface, we hypothesized that intact virions may contain linear epitopes that are not immunogenic in the presence of the immunodominant conformational epitopes, but may well be recognized by antibodies generated by immunization with peptides. Information about antigenic sites exposed on native virions could be useful in the definition of neutralizing epitopes and design of effective immunogens for vaccination.
In the present study, the epitope exposure and crossreactivity among PV capsids was determined by analyses of the reactivity of PV particles or HPV capsid antigens in clinical specimens with antisera against 66 overlapping peptides from the L1 and L2 proteins of HPV-16.
Methods
Antigens. Peptides derived from the L1 and L20RFs of HPV-16 were synthesized by the solid phase method, as described previously (Dillner et al., 1990) . The peptides were conjugated to the carrier protein keyhole limpet haemocyanin and used for immunization of guinea pigs, as described (Dillner et al., 1991) . When tested in peptide ELISAs 95 % of immunized guinea pigs had responded, in most cases with antipeptide titres of 1 : 10000 or more.
HPV-16 L 1 and L2 virus-like particles (VLPs) were generated in Sf-9 insect cells by using a recombinant baculovirus (clone l14/K; generously provided by M. Dtirst and L. Gissmann, DKFZ, Germany) to coexpress L 1 and L2 of HPV-16, essentially as described previously (Kirnbauer et al., 1993) , except that L2 of the 'prototype' was replaced by L2 of clone 114/K in the double expression vector 114/K-LI/L2-pSynwVI- (Kirnbauer et al., 1993) . In short, the L20RF was amplified by PCR using Pfu polymerase, and SstII restriction sites included into the primers were used for cloning 114/K-L2 into the double expression vector pSynwVI-containing 114/K-L1 as described (Kirnbauer et al., 1993) . The vector-HPV junctions were sequenced and expression of L1 and L2 by recombinant baculovirus verified by Western blotting. Insect cells were infected for 72 h, lysed and VLPs purified on CsC1 gradients. Concentration of the particle preparation was determined by quantification of total L1 after polyacrylamide gel electrophoresis. L1 and L2 containing VLPs of the BPV-1 prototype strain were similarly prepared. HPV-11 particles were obtained from infected skin chips implanted under the renal capsule of nude mice as described (Kreider et al., 1985) , and purified on CsC1 gradients. BPV virions were purified from cow warts induced by inoculation of several wild-type strains of BPV-1, as described (Dillner et al., 1991) .
In situ hybridization (ISH) . This was performed in parallel with immunocytochemical staining to ascertain which HPV type each biopsy contained. ISH was performed either using biotin-labelled HPV probes (Vira Type in situ procedure, Life Technologies Inc; Biohit HPV in situ typing test, Biohit Oy) or with probes biotinylated by nick translation (Skyldberg et al., 1995) . ISH with the two kits were performed according to the manufacturer's instructions, whereas the other hybridizations were performed essentially as described (Skyldberg et al., 1995) . The tissue sections were treated before hybridization with 500 ktg/ml Proteinase K in phosphate-buffered saline (PBS), pH 7.2, for 15 min at 37 °C. ISH was performed at 50 °C and after hybridization slides were washed twice in 0.2 × SSC at 50 °C for 5 rain. Using ISH the infected tissues were typed for Capsid antigen detection. The antisera were tested by the peroxidaseantiperoxidase (PAP) staining method on formalin-fixed, paraffinembedded sections of cervical condylomas, CIN lesions and common warts. Sections (4/1m thick) were deparaffinized, rehydrated and treated with 3 % hydrogen peroxide in PBS. After blocking with 5 % milk powder in PBS for 60 min, the sections were incubated with antipeptide antisera, diluted 1 : 1000. In between PBS washes, sections were incubated with anti-guinea pig immunoglobulins (Dako), diluted 1 : 150, for 1 h, with swine anti-rabbit immunoglobulins (Dako), diluted 1 : 100, for 1 h and with a rabbit peroxidase-antiperoxidase complex (Dako), diluted 1 : 100, for 1 h. After a final PBS wash, the antibody complex was visualized by the addition of 3-amino-9-ethylcarbazole in acetate buffer (pH 4). Counter staining was performed with Mayer's haematoxylin for 15-30 s. The first and last section of each block were stained with a commercially available rabbit antiserum raised against SDS-treated BPV type 1 (Dako) for sections made until 1991, whereafter the monospecific antiserum 16a (Dillner et al., 1991) was used. These antisera detect PV group-specific antigens on the capsid protein and were used as a positive control.
ELISA. Guinea pig and rabbit antisera against 73 synthetic peptides derived from the L 1 and L20RFs of HPV-16 were tested for reactivity in ELISA against intact and disrupted BPV and HPV-16 VLPs (Kirnbauer et al., 1993) or HPV-11 particles (Kreider et al., 1985) . For disruption, virions were diluted to 1/tg/ml in 0.1 M-carbonate buffer (pH 9.6) and kept at room temperature (RT) for 4 h before coating onto ELISA plates. For analysis of intact virions or VLPs, dilution was in PBS immediately before coating. A 50/A volume of the dilution was added to each well of a Microtiter plate (Costar) and the plates were incubated at 4 °C overnight. After two washes with ice-cold PBS the plates were blocked with 10 % horse serum (heat-inactivated; Sigma) in PBS (HS-PBS) for 1 h. After discarding the blocking solution, antipeptide antisera produced either in guinea pigs or in rabbits, diluted 1:50 or 1:100 in HS PBS, were added to the plates and allowed to react for 2 h. After five washes with PBS-0.1% Tween 20 (PBS T), peroxidase-conjugated rabbit anti-guinea pig immunoglobulins, diluted 1:2000 or goat anti-rabbit immunoglobulins, diluted 1 : 1000 (Dako) in HS-PBS were added to the plates and incubated at RT for 2 h. The plates were developed with 0-4 mg/ml 2,2'-azinodi(3-ethylbenzthiazo-linsulphonate) deammonium salt in 0.1 M-citrate buffer (pH 4) with 0.9 % hydrogen peroxide and the absorbance at 405 nm was recorded after 15 min.
For catching antibody ELISA, the plates were coated with the IgG fraction of a rabbit antipeptide antiserum diluted 1 : 30 in PBS, at 4 °C overnight. After one wash with PBS-T and blocking with HS PBS for 1 h, the plates were incubated at 37 °C for 2 h with serial dilutions of VLPs diluted either in PBS (intact particles) or in 0.1 M-carbonate buffer (pH 9.6) (disrupted particles). After five washes with PBS-T, the plates were incubated with guinea pig antipeptide antisera, diluted 1 : 100 in HS-PBS for 1 h at 37 °C. After five washes with PBS T, peroxidase-conjugated guinea pig immunoglobulins (Dako), diluted 1 : 1000 in 8 % horse serum, and 2 % rabbit serum in PBS were added to the plates and incubated at 37 °C for 45 min. Development and recording of the colour reaction were as above.
Results

Epitopes displayed in sections of infected tissue
A total of 114 cervical biopsy specimens, mostly from low-grade dysplasias and condylomas, that were positive in ISH for HPV-6, -11, -16, -18, -31, -33 or -35 as well as two specimens that were negative in ISH were tested for expression of the HPV capsid antigen by immunostaining with an antiserum against BPV (Dako) and/or an antipeptide antiserum against an HPV group-specific epitope (Dillner et al., 1991). Seven specimens could not be tested due to poor quality of the sections or very small amounts of epithelium present. Of the cervical lesions 52/107 (49 %) were found to express the capsid antigen. However, we tested only 28/52 capsid antigen positive biopsies, because only in 28 cases was it possible to cut multiple consecutive sections where both the first and the last section were positive for the HPV capsid antigen.
Thirty-five consecutive sections from six biopsies were cut and tested with antisera to 35 peptides corresponding to the entire major capsid protein L1 (Table 1 a). Five biopsies were from cervical condylomas or CIN lesions positive for HPV-6, -16, -16/18, -31 or -33 and one was from a cutaneous wart (Table 2a ). The antisera which gave a nuclear staining with some of the six biopsies were tested further with one additional biopsy specimen from * +, positive staining; -, no staining. The HPV type of the lesion was determined by parallel in situ hybridization. Some biopsies were infected with two HPV types: t in (a) means that the specimens were positive for the given probe mix; $ in (b) means that the specimen was HPV-18 positive in one area and positive with a probe mix of HPV-6/11 and -31/33/35 in another.
a skin wart and six additional biopsies from cervical lesions positive for HPV-6/ll, -18 or -35, -31/33/35 (Table 2a) . As controls, we stained histological sections of ISH-negative cervical lesions with our antipeptide antisera from HPV-16 L1 and L20RFs. No staining was seen. Also, histological sections containing HPV capsid proteins were tested with preimmune sera and no staining was detectable in the capsid antigen-containing cells.
Of the 35 antipeptide antisera 11 gave a specific nuclear staining in the same cells that were also positive in stainings with PV group-specific antisera (Table 2a) (exemplified in Fig. 1 a, b ) and in the same area of the epithelia that contained HPV DNA when tested by ISH. Some epitopes appeared to be shared by most human papillomavirus types, e.g. peptide numbers Ll:13 and Ll:16 (at positions 182-201 and 227-246), since they were displayed also in the HPV capsid antigens found in cutaneous warts. Most antisera only stained genital type HPV capsids, but none of the L1 antisera gave an HPV-16 type-specific staining (Table 2a ). The number of positive cells and the intensity of the immunostainings varied with the different antipeptide sera. Strong staining intensities were mostly obtained with the antisera against peptide numbers 13, 16, 20 and 22. The strongest staining intensities were consistently given by the antisera against peptides 16a and 16, which were also the most crossreactive antipeptide sera.
Thirty-one sections from two specimens, one from an HPV-16 positive lesion and the other from a HPV-33 positive dysplasia, were tested with 31 antisera against peptides corresponding to the entire L2 protein (Table   2b ). Seven of the antipeptide antisera (against peptide numbers 38, 44, 46, 60, 61, 62 and 63; Table 2b) gave a specific nuclear staining in the virus-producing tissue. Sections from 15 additional biopsies from cervical lesions infected with were tested for reactivity with the seven reactive antisera. The strongest staining and the highest number of stained nuclei were obtained with the antisera against peptides L2:44, L2:46 and L2:60 (Table 2b , Fig.lc) . The antipeptide antisera against peptides number 38, 44 and 46 stained the HPV capsid antigen of several different genital types of HPV whereas the antiserum against peptide 60 reacted only with HPV-16 and HPV-33 positive lesions and the antisera against peptides L2:61, L2:62 and L2:63 reacted only with HPV-16 positive specimen(s) ( Table 2b ).
Epitopes exposed on intact or disrupted HPV-16 viruslike particles
All antipeptide antibodies were screened for reactivity with intact and disrupted HPV-16 and BPV VLPs and native and denatured HPV-11 particles in ELISA at a 1 : 100 dilution. Antisera against 20 peptides from HP¥-16 L1 reacted with intact HPV-16 VLPs (Fig. 2a) . Most of the reactive sera had also been reactive with the PV capsid antigen in immunohistocytochemical stainings (cf . Table 2a ). Antisera against 12 HPV-16 L1 peptides were also reactive with disrupted virus (Fig. 2a) . Some P. Heino and others sera, e.g. against peptide numbers 8, 10, 14, 16 and 29, reacted about as well with disrupted as with intact particles (Fig. 2a) . Several antipeptide antisera (e.g. L1:3, L1:20 and L1:31) were much more reactive with intact than with disrupted particles (Fig. 2a) . All 31 antisera against peptides corresponding to the L2 protein of HPV-16 were also tested for reactivity with HPV-16 and BPV VLPs as well as with HPV-11 virions. Seven antipeptide antisera reacted with intact HPV-16 VLPs (Fig. 2b) . Both for L1 and L2, preimmunization sera from the same animals were tested in parallel with the reactive sera. Weak reactivity ( < 30% of the postimmunization sample) was detected in one prebleed, whereas prebleeds from all other animals showed no detectable reactivity (ELISA A < 0.050). The five antisera that showed the strongest reactivity with intact HPV-16 VLPs, as well as a rabbit antiserum to one of these peptides, were titrated in serial 3-fold dilutions for reactivity against the immunizing peptides and intact HPV-16 VLPs. Two guinea pig antisera and one rabbit serum were reactive at a 1 : 146000 titre (Table  3) . Interestingly, two guinea pig antisera had an identical titre against HPV-16 VLPs and against the immunizing peptide ( Table 3 ), indicating that these synthetic immunogens mostly or exclusively induce antibodies reactive with intact HPV-16 VLPs.
Exposure of cross-reactive epitopes on HPV-11 virions
Reactivity with HPV-11 was studied using purified virions obtained from infected foreskins explanted under the renal capsule of nude mice. The material was only available in limited amounts and the HPV-11 ELISA had a lower sensitivity than the VLP ELISAs. Five of the L1 antipeptide antisera and four of the L2 antipeptide antisera (against peptides L1:10, Ll:13, L1:20 L1:29, L1:32, L2:37, L2:46, L2:51, L2:58 and L2:60) reacted weakly with intact purified HPV-11. Eleven out of 38 HPV-16 L 1 antipeptide sera were reactive with disrupted HPV-11 (Fig. 3) .
Exposure of cross-reactive epitopes on BPV
In a previous study (Dillner et al., 1991) , we defined three major broadly cross-reactive antigenic sites in the L1 protein by testing disrupted BPV virions for reactivity .q .q ~ ~.q .q .q .q .q.q.q.q.q .q.q ~q .q .q ~.q.q .q.q.q.q .q.q.q.q ~ .q with antisera against HPV-16-derived peptides. The most reactive site was positioned in the middle of L1 and was designated 16a, whereas the other two sites (30b and 33a) are positioned in the L1 carboxy terminus. We now tested both L1 and L2 guinea pig antipeptide antisera and several rabbit antisera against the major crossreactive sites for reactivity with purified BPV virions of multiple viral strains, as well as with BPV-l VLPs+ Different viral isolates were found to differ in their epitope exposure: some viral isolates showed strong reactivity with the 16a antiserum and weak reactivity with the antisera to the carboxy-terminal epitopes, whereas others strains were mainly reactive with the * Reactivity of various BPV-1 strains and BPV VLPs with antisera against an internal group-specific site (16a) and carboxy-terminal group-specific sites (30c or 33a). The reactivity of guinea pig antipeptide 16a antisera is compared with the reactivity of antisera against the carboxy-terminal peptides 30c or 33.
t Purified FcPV (common chaffinch papillomavirus) reacted strongly with anti-16a, but not detectably with the antisera to carboxyterminal epitopes.
antisera to the carboxy-terminal epitopes (Table 4 ). The epitope exposure pattern was consistent within viral strains, since several different virus preparations from different cow warts induced by the same strain gave similar results. Of all disrupted BPV particles tested, the BPV VLPs showed the lowest reactivity with the 16a guinea pig antipeptide serum (Table 4) , although two rabbit antisera against this peptide were reactive (Fig. 4) . with the mean of replicate values of control plates coated only with buffer subtracted. HPV-16 and BPV assays were performed six times; HPV-11 assays were performed twice. The mean coefficient of variation (CV) was 3.2 % and less than 3 % of data sets had a CV > 10%. A difference in absorbance (AA) of < 0.2 was considered negative. Several guinea pig and rabbit antisera against the previously described broadly cross-reactive sites were also reactive with the BPV VLPs (Fig. 4) . The antiserum against peptide L1:3 showed a broad cross-reaction with intact BPV VLPs, as was also noted previously (Dillner et al., 1991) . Three broadly cross-reactive sites were also detected in the L2 protein (Fig. 4) .
Verification of epitope exposure on non-disrupted virions by two-site ELISA
Exposure to a high-pH carbonate buffer is the original method for disruption of papillomaviruses used in many classical studies (Christensen et al., 1992; Cowsert et al., 1987; Favre et al., 1975) . In order to quantify the disruption efficiency and exclude the possibility that the reactivity with native virions was due to contaminating monomers, we used a two-site antibody ELISA. ELISA plates were coated with antibodies against peptide L 1 : 20, whereafter VLPs, diluted either in carbonate buffer or PBS were added. Subsequently, antipeptide antisera against the same or other L1 peptides were allowed to react with the particles bound by the first antibody. As shown in Fig. 5 , virus diluted in PBS could bind two antibodies against the same site, demonstrating that the virus existed as multimers of the capsid protein and indicating that the L1:20 epitope is indeed exposed on intact virions. In contrast, virus diluted in carbonate buffer could only bind the Ll:20 antibodies once, indicating that the virus had been disrupted into monomers of the capsid protein. The inability to detect bound virus in this buffer is not because of a destruction of the Ll:20 epitope in carbonate buffer, since it was possible to bind the capsid protein to the coated anti-L1:20 antibodies and detect it with antibodies against another antigenic site (Fig. 5) .
Discussion
The delineation of the antigenic structure of the HPV capsid is important for several reasons. The availability of a panel of site-directed antisera against epitopes with varying degrees of cross-reactivity among HPV types could be important for studies of the expression of the HPV capsid during the viral life cycle, for studies of viral infectivity and contagiousness, and might also enable HPV detection and typing by simple immunological techniques such as immunoperoxidase staining or twosite ELISA. Although no antipeptide antisera could be found that were both strongly reactive and exclusively type-specific for HPV-16, several antisera were found that showed a strong, type-restricted staining. In particular, the strongly stained L2 epitope L2: 60 was found only in tissue infected by HPV-16 and the closely related HPV-33. The 12 amino-terminal amino acids in peptide 60 are identical to HPV-33 but not to other genital HPV types, whereas peptides 61 to 63 share very little homology with HPV-33 or the other genital HPV types. This is in accordance with the type-restricted reactivity of the corresponding antisera. A putative type-restricted epitope reactive with human sera has been defined in this region (Lehtinen et al., 1993) .
The location of the L2 protein in PV capsids is unclear (Baker et al., 1991) . Monoclonal antibodies raised against a bacterially derived fusion protein of BPV L2 reacted only with internal antigenic sites in BPV (Jin et al., 1989) . However, Christensen et al. (1991) found that an antiserum against bacterially expressed cotton tail rabbit PV (CRPV) L2 had some neutralizing activity, thus demonstrating that at least part of CRPV L2 is externally located. We find that some antisera raised against peptides from HPV-16 L2 react mainly with intact VLPs, confirming that part of the L2 protein is exposed on the surface of the VLPs.
By immunocytochemical staining we could define 11 antigenic sites on the HPV L1 protein. Some antigenic sites (such as Ll:20 and L1:22) were only found on genital-type HPVs, whereas other sites were broadly cross-reactive among HPV types. The peptides that induced the most cross-reactive antisera (peptides L I:I 3 and L I:16) showed complete amino acid homology among the HPV types investigated, including cutaneous wart virus, in 50-95% and 60-90% of amino acid positions, respectively. In addition, several conservative amino acid substitutions were present.
The carboxy-terminal part of L 1 was not stainable in immunohistocytochemistry by any of the antipeptide antisera, even though the antisera to peptides 28-31 reacted strongly with intact and/or disrupted HPV-16 VLPs (Table 2) , and antisera to peptides 31 and 33 and to truncated analogues of these peptides also reacted with purified BPV particles in ELISA (Dillner et al., 199l) , and some reactivity was also detected with intact and/or disrupted HPV-11 (Fig. 3) . Conceivably, the carboxy-terminal part of L1 may be masked by the processing procedure with formalin-fixation and paraffin-embedding, which frequently may damage or eliminate epitopes. In a few instances, staining with the same antiserum of different tissues infected with the same type of virus produced different results. The most likely explanation is that the relative amounts of L l and L2 proteins vary between different biopsies, with the result that some antisera may not be sufficiently sensitive to detect low-level expression. Alternatively, the tissues could be infected with different subtypes of the same virus that have a different epitope exposure.
The major immunogenic linear epitopes seen by the human immune response in infected individuals have been reported previously (Dillner et al., 1990 (Dillner et al., , 1994 . The major immunogenic epitopes (L1 : 13, L1 : 14, L1 : 16 and L1:31) all correspond to major antigenic epitopes, but many of the major antigenic epitopes are poorly reactive or unreactive with human sera. Previously, monoclonal antibodies have been raised against a bacterial fusion protein containing a part (residues 197-400) of HPV-16 L1 . The binding sites of these monoclonal antibodies on HPV-16 L1 were located between residues 295-310 and 325-339 (Cason et al., 1989) . The staining pattern of these monoclonal antibodies was type-restricted, although cross-reactivity with HPV-2 was found. Our antipeptide antibodies directed at the corresponding region of L1 (peptides 20, 21 and 22 at positions 287-306, 302-321 and 317-336) stained most genital HPV types tested and did not stain the skin warts, indicating that the epitopes recognized by our sera are not the same as those studied by Cason et al. In a subsequent study, four unconjugated synthetic peptides derived from L1 of BPV type 2 were injected into rabbits, whereafter 3/4 (75 %) rabbit sera were found to induce clumping of viral particles (Cason et al., 1993) . None of the regions thus identified as potentially surface-exposed correspond to the major surface-exposed regions identified in this study. However, since a very large proportion (13/35) of our L1 peptides induced antisera that were reactive with intact capsids to at least some extent, it is highly likely that minor surface-exposed linear epitopes may be found at many sites along the L1 major capsid protein. Volpers et al. (1993) found that immunization with the HPV-33 L2 protein induced antibodies against an epitope in the middle of L2. An antigenic epitope was not detected at the same site in this study, which could either be due to a difference between HPV-33 and HPV-16 or because the region corresponding to this epitope was divided across two peptides (L2:42 and L2:43) in this study. However, the identification of immunodominant B cell epitopes seen after infection or hyperimmunization using whole proteins (Cason et al., 1989; Yaegashi et al., 1992 ) is of limited relevance for the design of peptide immunogens for use in production of useful anti-virus antisera or as peptide vaccines, since even linear immunodominant B cell epitopes exposed in the context of the whole protein may be very hard to mimic as peptide immunogens. Conversely, subdominant or cryptic epitopes that are not detectable after immunization with whole proteins may work very well as peptide immunogens. No previous studies have attempted a systematic evaluation of HPV peptide immunogens and comparisons with epitopes detected in other systems are not particularly meaningful.
Knowledge of exposed antigenic structures of HPV is important for the design of preventative vaccines. Immunization with intact PV particles generates mainly a type-specific response, in spite of the fact that the major HPV capsid protein is highly conserved among HPV types. Since there exists a very large number of malignancy-associated genital HPV types, type-specific vaccines would only be partially effective in preventing HPV-associated neoplasia. However, the present study has found that when synthetic immunogens that do not contain the immunodominant and conformationally dependent epitopes of the HPV capsids are used, it is possible to induce high-titre responses against intact HPV capsids and that several such responses are not type-restricted to HPV-16. Unfortunately, an HPV-16 infectivity assay for measurement of neutralizing activity is not available, and it therefore remains unknown whether the surface-exposed epitopes identified in the present study are possible targets for synthetic peptidebased vaccines. Among the major epitopes identified, LI: 14 and Ll:20 are promising because of the high titre against HPV-16 of the corresponding antisera. Epitopes Ll:3 and L1:29 are promising because of their identical titres against the immunizing peptide and against the virus, suggesting that merely improving immunogenicity in order to obtain higher titres of antipeptide antibodies also would result in higher anti-virus titres. The fact that anti-L1:3 also reacted with intact BPV, in spite of its low anti-peptide titre, is also promising for the prospects of designing a broadly cross-reactive PV vaccine. The fact that this antiserum was much more reactive with intact than with disrupted virions indicates that the conformation of the immunogen is more similar to the structure of the epitope found in the intact virus than in the capsid protein monomers.
Peptide 16a is, in spite of the high anti-virus titres of the antipeptide antisera, not considered a promising candidate for vaccination studies. This antigenic region has the character of an antigenic hot spot, with several different partially overlapping epitopes positioned close to each other (Dillner et al., 1991) . For example, a 28 residue peptide (15-17) containing the 16a epitope was found to induce type-specific antibodies (Christensen et al., 1990a) , whereas the 16a antisera were reactive with disrupted virions from both animal and human PVs and only for some immunized animals were antibodies against intact virions detected. However, this antiserum produced the strongest immunocytochemical staining of the nuclei of virus producing cells of all reagents tested, and is very useful for high sensitivity detection of productive HPV infection.
In conclusion, the present identification and characterization of antigenic sites on the HPV capsids could be important both for the immunological detection and characterization of human papillomavirus particles in clinical specimens and for the design of immunogens for vaccination studies.
